The epidemiology of hepatitis C virus in Central Asia

Systematic review, meta-analyses, and meta-regression analyses

Welathanthrige S.P. Botheju, Fawzi Zghyer, Sarwat Mahmud, Assel Terlikbayeva, Nabila El-Bassel, Laith Aburaddad

Research output: Contribution to journalArticle

Abstract

The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7% (95%CI: 0.7–0.8%) in Kazakhstan, 2.0% (95%CI: 1.7–2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7–3.6%) in Tajikistan, and 9.6 (95%CI: 5.8–14.2%) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5% (95%CI: 10.9–16.4%) among non-specific clinical populations, 31.6% (95%CI: 25.8–37.7%) among populations with liver-related conditions, and 51.3% (95%CI: 46.9–55.6%) among people who inject drugs. Genotypes 1 (52.6%) and 3 (38.0%) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.

Original languageEnglish
Article number2090
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 1 Dec 2019

Fingerprint

Central Asia
Hepacivirus
Meta-Analysis
Epidemiology
Uzbekistan
Regression Analysis
Turkmenistan
Tajikistan
Kyrgyzstan
Kazakhstan
Population
Virus Diseases
Pharmaceutical Preparations
Genotype
Guidelines
Delivery of Health Care
Liver
Incidence

ASJC Scopus subject areas

  • General

Cite this

The epidemiology of hepatitis C virus in Central Asia : Systematic review, meta-analyses, and meta-regression analyses. / Botheju, Welathanthrige S.P.; Zghyer, Fawzi; Mahmud, Sarwat; Terlikbayeva, Assel; El-Bassel, Nabila; Aburaddad, Laith.

In: Scientific reports, Vol. 9, No. 1, 2090, 01.12.2019.

Research output: Contribution to journalArticle

Botheju, Welathanthrige S.P. ; Zghyer, Fawzi ; Mahmud, Sarwat ; Terlikbayeva, Assel ; El-Bassel, Nabila ; Aburaddad, Laith. / The epidemiology of hepatitis C virus in Central Asia : Systematic review, meta-analyses, and meta-regression analyses. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{f8425bc9d91e45b99197b1192774eaa0,
title = "The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses",
abstract = "The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7{\%} (95{\%}CI: 0.7–0.8{\%}) in Kazakhstan, 2.0{\%} (95{\%}CI: 1.7–2.4{\%}) in Kyrgyzstan, 2.6{\%} (95{\%}CI: 1.7–3.6{\%}) in Tajikistan, and 9.6 (95{\%}CI: 5.8–14.2{\%}) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5{\%} (95{\%}CI: 10.9–16.4{\%}) among non-specific clinical populations, 31.6{\%} (95{\%}CI: 25.8–37.7{\%}) among populations with liver-related conditions, and 51.3{\%} (95{\%}CI: 46.9–55.6{\%}) among people who inject drugs. Genotypes 1 (52.6{\%}) and 3 (38.0{\%}) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.",
author = "Botheju, {Welathanthrige S.P.} and Fawzi Zghyer and Sarwat Mahmud and Assel Terlikbayeva and Nabila El-Bassel and Laith Aburaddad",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-38853-8",
language = "English",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - The epidemiology of hepatitis C virus in Central Asia

T2 - Systematic review, meta-analyses, and meta-regression analyses

AU - Botheju, Welathanthrige S.P.

AU - Zghyer, Fawzi

AU - Mahmud, Sarwat

AU - Terlikbayeva, Assel

AU - El-Bassel, Nabila

AU - Aburaddad, Laith

PY - 2019/12/1

Y1 - 2019/12/1

N2 - The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7% (95%CI: 0.7–0.8%) in Kazakhstan, 2.0% (95%CI: 1.7–2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7–3.6%) in Tajikistan, and 9.6 (95%CI: 5.8–14.2%) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5% (95%CI: 10.9–16.4%) among non-specific clinical populations, 31.6% (95%CI: 25.8–37.7%) among populations with liver-related conditions, and 51.3% (95%CI: 46.9–55.6%) among people who inject drugs. Genotypes 1 (52.6%) and 3 (38.0%) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.

AB - The objective was to delineate hepatitis C virus (HCV) epidemiology in countries of Central Asia (CA), specifically Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan. A systematic review was conducted guided by the Cochrane Collaboration Handbook, and reported using PRISMA guidelines. Meta-analyses were performed using DerSimonian-Laird random-effects models with inverse variance weighting. Random-effects meta-regression analyses were performed on general population studies. The systematic review identified a total of 208 HCV prevalence measures. No incidence or Turkmenistan studies were identified. Meta-analyses estimated HCV prevalence among the general population at 0.7% (95%CI: 0.7–0.8%) in Kazakhstan, 2.0% (95%CI: 1.7–2.4%) in Kyrgyzstan, 2.6% (95%CI: 1.7–3.6%) in Tajikistan, and 9.6 (95%CI: 5.8–14.2%) in Uzbekistan. Across CA, the pooled mean prevalence was 13.5% (95%CI: 10.9–16.4%) among non-specific clinical populations, 31.6% (95%CI: 25.8–37.7%) among populations with liver-related conditions, and 51.3% (95%CI: 46.9–55.6%) among people who inject drugs. Genotypes 1 (52.6%) and 3 (38.0%) were most frequent. Evidence was found for statistically-significant differences in prevalence by country, but not for a temporal decline in prevalence. CA is one of the most affected regions by HCV infection with Uzbekistan enduring one of the highest prevalence levels worldwide. Ongoing HCV transmission seems to be driven by injecting drug use and healthcare exposures.

UR - http://www.scopus.com/inward/record.url?scp=85061598237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061598237&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-38853-8

DO - 10.1038/s41598-019-38853-8

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 2090

ER -